We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NAVN:NASDAQNavan, Inc. Analysis

Data as of 2026-07-17 - not real-time

$25.80

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Navan, Inc. shows a technically bullish backdrop as the short‑term moving average sits above the medium‑term average, which in turn is above the long‑term average, reinforcing upward momentum. The RSI is in the upper half of its range, indicating continued strength, while the MACD histogram has slipped negative, warning of a possible short‑term pullback. Volume has been tapering, and beta hovering around one points to market‑aligned volatility, yet the 30‑day volatility reading remains elevated, flagging price swings.
Fundamentally, the company is delivering rapid revenue expansion and maintains a strong gross margin, but operating and net margins are still in the red, and return metrics are negative. Valuation metrics are stretched, with the price‑to‑earnings multiple far exceeding the sector average and a discounted cash‑flow model suggesting the stock trades well above intrinsic value. A recent strategic partnership with a major industrial firm could broaden the customer base and support future growth, but the lack of dividend and current profitability challenges temper optimism.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram indicating near‑term downside pressure
  • Valuation gap between market price and DCF estimate
  • Strong technical momentum but weakening volume

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Accelerating revenue growth and high gross margin
  • Forward earnings turning positive
  • Strategic corporate partnership expanding addressable market

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Need for sustained profitability to justify premium valuation
  • Elevated volatility and beta suggesting market‑linked risk
  • Absence of dividend and reliance on growth narrative

Key Metrics & Analysis

Financial Health

Revenue Growth39.90%
Profit Margin-46.70%
P/E Ratio78.2
ROE-52.90%
ROA-8.38%
Debt/Equity13.95
P/B Ratio5.3
Op. Cash Flow$22.3M
Free Cash Flow$3.9M
Industry P/E33.2

Technical Analysis

TrendBullish
RSI61.7
Support$18.35
Resistance$28.22
MA 20$24.11
MA 50$21.57
MA 200$15.97
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5

Valuation

Fair Value$2.54
Target Price$29.60
Upside/Downside14.73%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.97
Volatility73.71%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.